Low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC)
TYRATyra BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TYRA-300 in Low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The expected timing is based on the latest available company guidance and may change.
SURF302 trial. 1/10/25- Received IND clearance. 6/30/25- Dosed first patient. 8/14/25- Initial 3-month CR data in H1 2026. 11/05/25:- SURF302 Phase 2 study is enrolling and the company remains on track to report initial three-month complete response data in H1 2026. 03/02/26:- SURF302 opened additional US and international sites; initial three-month complete response data expected by end H1 2026. 08/04/26:- SURF302 initial data expected September 2026; more than 40 patients enrolled.
Verification
Confirm timing and program details against the company announcement or filing.